Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Upstream Bio, Inc. (UPB : NSDQ)

• Company Description    Upstream Bio Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in development which targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio Inc. is based in WALTHAM, Mass. Number of Employees: 52

• Price / Volume Information    Yesterday's Closing Price: $27.15 Daily Weekly Monthly 20 Day Moving Average: 519,657 shares Shares Outstanding: 54.04 (millions) Market Capitalization: $1,467.15 (millions) Beta: 1.90 52 Week High: $33.00 52 Week Low: $5.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.13% -1.96% 12 Week 37.19% 34.98% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 890 Winter Street Suite 200 - Waltham,MA 02451 USA ph: 781-208-2466 fax: - ir@upstreambio.com http://www.upstreambio.com

• General Corporate Information    Officers E. Rand Sutherland - Chief Executive Officer and Director Ronald C. Renaud, Jr. - Chairman Michael Paul Gray - Chief Financial and Operating Officer Daniella Beckman - Director Erez Chimovits - Director Peer Information Upstream Bio, Inc. (CORR.) Upstream Bio, Inc. (RSPI) Upstream Bio, Inc. (CGXP) Upstream Bio, Inc. (BGEN) Upstream Bio, Inc. (GTBP) Upstream Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 91678A107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/11/26 Share - Related Items Shares Outstanding: 54.04 Most Recent Split Date: (:1) Beta: 1.90 Market Capitalization: $1,467.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.87 Price/Cash Flow: - Price / Sales: 524.17 EPS Growth vs. Year Ago Period: 90.95% vs. Previous Quarter: 14.86% Sales Growth vs. Year Ago Period: 12.52% vs. Previous Quarter: -27.11% ROE 12/31/25 - - 09/30/25 - -28.71 06/30/25 - -35.90 ROA 12/31/25 - - 09/30/25 - -27.94 06/30/25 - -26.26 Current Ratio 12/31/25 - - 09/30/25 - 32.67 06/30/25 - 38.27 Quick Ratio 12/31/25 - - 09/30/25 - 32.67 06/30/25 - 38.27 Operating Margin 12/31/25 - - 09/30/25 - -4,366.77 06/30/25 - -3,836.58 Net Margin 12/31/25 - - 09/30/25 - -4,366.77 06/30/25 - -3,836.58 Pre-Tax Margin 12/31/25 - - 09/30/25 - -4,366.77 06/30/25 - -3,836.58 Book Value 12/31/25 - - 09/30/25 - 7.02 06/30/25 - 7.60 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©